Grant of Share Options

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

Grant of Share Options

The Company today announces that, pursuant to the rules of the Company's Share Option Plan 2010, it yesterday granted options to Dr Liz King, Director of Research and Development*, to subscribe for up to a total of 4,200,000 ordinary shares of 0.1p each ("Ordinary Shares") at an exercise price of £0.11875 per ordinary share (the "Options"), amounting to 0.42% of the current issued share capital of the Company.

The Options have been granted under the Company's EMI approved Option Scheme and the Unapproved share option plan 2010. Further details of the Options granted are as follows, with each tranche subject to certain performance conditions in addition to the share price vesting criteria shown below:

* Dr King's role is a non-board position

** Based on the middle-market closing price (as derived from the AIM Appendix of the Daily Official List) of theCompany's Ordinary Shares for a consecutive period of 10 days.

Following the grant of the Options the total number of ordinary shares subject to options and which could, in the future, be issued is 89,200,000. This represents 8.87% of the current issued share capital of the Company which comprises 1,005,661,619 Ordinary Shares.

For further information:

Oxford Pharmascience Group Plc

Marcelo Bravo, Chief Executive +44 20 7554 5875

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell/Jen Boorer +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers, but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. 

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.